BofA lowered the firm’s price target on Bausch + Lomb (BLCO) to $11 from $17 and keeps an Underperform rating on the shares. EBITDA missed by 23%, primarily because of the enVista recall inventory write off and a slowdown in the U.S. generics business, and B+L lowered its FY25 EBITDA guidance by $50M at the midpoint to $850M-$900M, noted the analyst, who also points out that the lower guidance does not include tariffs. The firm lowered its 2025 and 2026 EPS views to 31c and 64c from 62c and 91c, respectively, and cites lower peer multiples as well as a lower EBITDA estimate for its revised target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target lowered to $13 from $14 at Citi
- Bausch + Lomb Corporation: Sell Rating Amid Financial Pressures and Uncertain Tariff Impacts
- Bausch + Lomb Reports Q1 2025 Financial Results
- Bausch + Lomb’s Earnings Call Highlights Growth Amid Challenges
- Hold Rating for Bausch + Lomb: Navigating Profitability Challenges and Uncertainties
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue